Physician

Wendy Stock

According to 2025 Medicare claims, Wendy Stock (NPI: 1588727093) practices hematopoietic cell transplantation and cellular therapy in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is UNIVERSITY OF CHICAGO (NPI: 1821048786; TIN: 36-2177139) and primary practice location at 60637-1447. Stock is affiliated with the UCMCNACO, LLC (ACO ID: A3531), participating under the MSSP model.

Stock's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 114 traditional Medicare patients, billed 453 HCPCS/CPT codes, and received $39,007 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 291 prescription claims across 38 beneficiaries totaling $3,566,878 in drug costs, led by Iclusig (Ponatinib Hcl). 2020 DME data shows 48 claims. Open Payments data shows 34 records totaling $961,483. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $30,546 and ending at $39,007. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,360,623 to $3,566,878. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	83	397	$30,546
2016	86	383	$33,481
2017	84	472	$42,414
2018	102	477	$47,432
2019	96	408	$37,627
2020	89	387	$34,321
2021	106	519	$46,462
2022	98	338	$26,540
2023	95	313	$27,371
2024	114	453	$39,007

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	37	350	$1,360,623
2016	29	242	$904,908
2017	37	382	$981,036
2018	41	361	$1,552,752
2019	46	324	$1,573,629
2020	42	398	$1,883,496
2021	39	237	$2,158,391
2022	34	208	$1,504,815
2023	32	176	$2,017,264
2024	38	291	$3,566,878

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$139,516
2020	N/R	48	$285,965
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	12	14	$135
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	21	41	$107
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	42	218	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	51	106	$69
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	22	36	$45

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Iclusig	Ponatinib Hcl	55	1,635	$1,104,104
Venclexta	Venetoclax	48	1,316	$393,608
Calquence	Acalabrutinib Maleate	24	720	$370,131
Xospata	Gilteritinib Fumarate	11	330	$273,709
Tasigna	Nilotinib Hcl	18	504	$181,239

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	5	$5,339	SERVIER AFFAIRES MEDICALES
Research Payments	Reported research-related payment or transfer-of-value amount.	29	$956,144	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Wendy Stock?

Tedicare shows public-source Medicare data for Wendy Stock (NPI 1588727093), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Wendy Stock have ACO affiliation data?

Wendy Stock is shown with ACO affiliation data for UCMCNACO, LLC (MSSP, ACO ID A3531).

What billing organization is linked to Wendy Stock?

Wendy Stock is linked to UNIVERSITY OF CHICAGO (billing NPI 1821048786) in the available physician profile data.

Does Wendy Stock have Open Payments data?

Wendy Stock has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.